Literature DB >> 8418184

Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men.

D H Osmond1, E Charlebois, H W Sheppard, K Page, W Winkelstein, A R Moss, A Reingold.   

Abstract

Serum samples from 735 homosexual or bisexual men were tested for antibodies to hepatitis C virus (HCV) and serologic markers of hepatitis B virus (HBV), and risk factors for each infection were compared. Thirty-four (4.6%) were confirmed HCV-positive compared with 81% positive for one or more HBV serologic marker(s). History of intravenous drug use (IVDU) and blood transfusion were significantly associated with HCV positivity (odds ratio [OR] = 14.3 and 4.4, respectively), but neither was significantly associated with HBV positivity. Sexual behavior was significantly associated with infection with both viruses. When IVDU and blood transfusion were controlled for, HCV infection was marginally associated with > 50 sex partners/year (OR = 2.1), > 25 oral receptive partners (OR = 2.4), and > 25 anal receptive partners (OR = 1.9). HBV infection was more strongly associated with the same variables. HCV infection is uncommon in homosexual men and IVDU is the primary route of transmission, but sexual transmission also occurs, albeit infrequently.

Entities:  

Mesh:

Year:  1993        PMID: 8418184     DOI: 10.1093/infdis/167.1.66

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Seroprevalence of HIV, HCV and syphilis in Brazilian prisoners: preponderance of parenteral transmission.

Authors:  E Massad; M Rozman; R S Azevedo; A S Silveira; K Takey; Y I Yamamoto; L Strazza; M M Ferreira; M N Burattini; M N Burattini
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

2.  A study on the role of the family and other risk factors in HCV transmission.

Authors:  S Brusaferro; F Barbone; P Andrian; G Brianti; L Ciccone; A Furlan; D Gnesutta; S Stel; E Zamparo; P Toniutto; P Ferroni; V Gasparini
Journal:  Eur J Epidemiol       Date:  1999-02       Impact factor: 8.082

3.  Risk of hepatitis C virus infection from tattooing and other skin piercing services.

Authors:  G H Shimokura; P R Gully
Journal:  Can J Infect Dis       Date:  1995-09

4.  Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HIV-1 infection and injecting drug use but not sexual behaviour.

Authors:  N J Bodsworth; P Cunningham; J Kaldor; B Donovan
Journal:  Genitourin Med       Date:  1996-04

Review 5.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

6.  Clinical presentation and course of acute hepatitis C infection in HIV-infected patients.

Authors:  Annie Luetkemeyer; C Bradley Hare; John Stansell; Phyllis C Tien; Edwin Charlesbois; Paula Lum; Diane Havlir; Marion Peters
Journal:  J Acquir Immune Defic Syndr       Date:  2006-01-01       Impact factor: 3.731

Review 7.  Oral sex and the transmission of viral STIs.

Authors:  S Edwards; C Carne
Journal:  Sex Transm Infect       Date:  1998-02       Impact factor: 3.519

8.  Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men.

Authors:  Michel Alary; Jean R Joly; Jean Vincelette; René Lavoie; Bruno Turmel; Robert S Remis
Journal:  Am J Public Health       Date:  2005-03       Impact factor: 9.308

9.  Association between hepatitis C virus seroreactivity and HIV infection in non-intravenous drug abusing prostitutes.

Authors:  J A Pineda; A Rivero; C Rey; J Hernández-Quero; A Vergara; J Muñoz; I Aguado; J Santos; R Torronteras; J A Gallardo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

10.  Long-term serologic follow-up of hepatitis C virus-seropositive homosexual men.

Authors:  O K Ndimbie; S Nedjar; L Kingsley; P Riddle; C Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.